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• Farletuzumab (FAR), a monoclonal antibody to folate receptor alpha, which is expressed in epithelial ovarian cancer (EOC).
• FAR has shown activity against EOC in platinum-sensitive relapse when combined with carboplatin and a taxane.
• Carboplatin in combination with pegylated liposomal doxorubicin (PLD) is a frequently used alterative regimen.
• This safety study assessed the addition of FAR to carboplatin/PLD, with a view toward future larger studies.
• This combination was generally well tolerated; adverse event proﬁle was similar to that of carboplatin/PLD alone.☆ Financial support: Funding for this study was provid
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Available online 28 November 2015Objective. Farletuzumab is a humanized monoclonal antibody that binds to folate receptor alpha, over-
expressed in epithelial ovarian cancer (EOC) but largely absent in normal tissue. Previously, carboplatin plus
pegylated liposomal doxorubicin showed superior progression-free survival and an improved therapeutic
index compared with carboplatin/paclitaxel in relapsed platinum-sensitive EOC. This study assessed safety of
farletuzumab/carboplatin/pegylated liposomal doxorubicin in women with platinum-sensitive recurrent EOC.
Methods. This multicenter, single-arm study enrolled patients with platinum-sensitive EOC in ﬁrst or second
relapse for treatment with weekly farletuzumab 2.5 mg/kg plus carboplatin AUC5-6 and pegylated liposomal
doxorubicin 30 mg/m2 every 4 weeks for 6 cycles. Subsequently, maintenance with single-agent farletuzumab
2.5 mg/kg once weekly or farletuzumab 7.5 mg/kg once every three weeks continued until progression. The
primary objective was to assess the safety of farletuzumab/carboplatin/pegylated liposomal doxorubicin.
Results. Fifteen patients received a median of 12.0 cycles (range, 3–26) of farletuzumab as combination
therapy or maintenance, for a median of 45.0 weeks (range 9–95). Farletuzumab/carboplatin/pegylated
liposomal doxorubicin was generally well tolerated, with no farletuzumab-related grades 3–4 adverse events.
The most commonly reported adverse events were associated with combination chemotherapy: fatigue
(73.3%), nausea (46.7%), and neutropenia (40%). Ten patients had grade ≥3 adverse events, most frequently
neutropenia and fatigue. No cardiac toxicity was seen. Best overall responses (RECIST)were a complete response
for one patient, partial responses for 10 patients, and stable disease for four patients.
Conclusions. Farletuzumabplus carboplatin/pegylated liposomal doxorubicin inwomenwith platinum-sensitive
EOC demonstrated a safety proﬁle consistent with that of carboplatin plus pegylated liposomal doxorubicin.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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to folate receptor alpha, known to be overexpressed in epithelial
ovarian cancer (EOC) but largely absent in normal tissue [1–4]. In
preclinical studies, FAR has exhibited immune-effector mediated effects
via antibody-dependent cell cytotoxicity (ADCC) and complement-
dependent cytotoxicity, and single-agent anti-tumor activity in
xenograft models of ovarian cancer, as well as synergistic effects with
chemotherapeutic agents [5,6]. The combination of carboplatin and
paclitaxel has long been utilized as a preferred treatment regimen for
platinum-sensitive EOC. This regimen was used in a Phase 2 study of
FAR in patients with EOC who had experienced ﬁrst relapse, with the
combination of carboplatin/paclitaxel/FAR found to be active as well
as well tolerated [7]. Recent studies have shown that FAR enhances
type 2 cell death in tumor cells and that the combination of combination
of these immune-effector cellular signaling pathway most likely result
in tumor growth suppression and toxicity [8].
Recent studies have suggested that the combination of carboplatin
and pegylated liposomal doxorubicin (PLD) may be the preferred regi-
men than carboplatin/paclitaxel for platinum-sensitive recurrent EOC
[9–11]. In a randomized Phase 3 noninferiority study [9] of carboplatin
plus PLD versus carboplatin plus paclitaxel in relapsed platinum-
sensitive ovarian cancer, the carboplatin/PLD combination demonstrat-
ed noninferiority with the comparator in terms of progression-free sur-
vival (PFS) (11.3months versus 9.4months; P=0.005) and lower rates
of severe and long-lasting neuropathy. The beneﬁt of carboplatin/PLD
over carboplatin/paclitaxel was noted to persist in analysis of patients
who relapsed between 6 and 12 and 6–24 months [11,12]. Toxicities
were more common with carboplatin/paclitaxel and included neutro-
penia, neuropathy, and hypersensitivity reactions. Interestingly,
carboplatin/PLD was associated with a substantially reduced incidence
of platinum-associated hypersensitivity reactions in this study. It should
be noted that the safety proﬁle of FAR consists of infrequent and mild
drug hypersensitivity adverse events (AEs) and rare interstitial
pulmonary changes. No adverse interaction with chemotherapy was
expected.
In view of a recent increase in the use of carboplatin plus PLD in
patients with platinum-sensitive EOC, a Phase 1b study of FAR plus
carboplatin and PLD was undertaken to assess the safety of this triple-
agent combination in this disease context.2. Methods
2.1. Study population
Eachparticipant providedwritten informed consent before initiating
study procedures. All enrolled patients were greater than 18 years old
and had histologically- or cytologically-conﬁrmed, platinum-sensitive
EOC (including primary peritoneal or fallopian tube malignancies)
with relapse as deﬁned by Gynecologic Cancer InterGroup (GCIG) CA-
125 criteria or protocol-speciﬁc modiﬁed (to reﬂect current practices
in the medical oncology community and nuances speciﬁc to ovarian
cancer) Response Evaluation Criteria in Solid Tumors (RECIST) v.1.0
for 6months or longer after completion of ﬁrst- or second-line platinum
chemotherapy. All had a Karnofsky Performance Status at least 70%.
Patients were required to have the following laboratory and clinical
results within two weeks prior to study day 1: absolute neutrophil
count (ANC) ≥1.5 × 109 cells/L; platelet count ≥100 × 109 cells/L;
hemoglobin ≥9 g/dL; creatinine ≤1.5 × upper limit of normal (ULN);
bilirubin ≤1.5 × ULN; aspartate aminotransferase (AST), alanine amino-
transferase (ALT), and alkaline phosphatase (ALK-P) b2.5 × ULN.
Women with known central nervous system (CNS) tumor involve-
ment, other active malignancy, clinically signiﬁcant cardiac disease,
active serious systemic disease or infection, evidence of immune orallergic reaction or documented antidrug antibodies (ADAs) after prior
monoclonal antibody therapy were excluded from participation.
2.2. Study design and treatment
This was a multicenter, open-label Phase 1b study with 2.5 mg/kg
intravenous (IV) FAR in combinationwith carboplatin and PLD to assess
the safety of this drug regimen in patients with platinum-sensitive EOC.
The primary objective of this study was to assess the safety of FAR/
carboplatin/PLD in this patient population. Hematology, clinical chemis-
tries, urine, and left ventricular ejection fraction (LVEF)weremonitored
on Day 1, Week 1 of every 4-week cycle. Tumor assessment (using
RECIST v.1.0) was performed every other cycle. Secondary objectives
included assessment of response and PFS and the pharmacokinetic
effect of FAR on chemotherapy (not reported here).
Study patients received carboplatin AUC5–6 IV and PLD 30 mg/m2 IV
on Day 1 of an every 4-week combination treatment cycle. An ANC of
1.5 × 109 cells/L was required for retreatment with chemotherapy. If
toxicity due to carboplatin or PLD occurred, doses could be reduced or
delayed according to institutional guidelines. If chemotherapy was
discontinued without disease progression, the investigator could elect
to continue the patient on single-agent FAR until disease progression.
Following completion of approximately 6 cycles with FAR/carboplatin/
PLD therapy, patients who had not progressed began maintenance
treatment with single-agent FAR 2.5 mg/kg once weekly in 4-week cy-
cles until disease progression. A protocol amendment based on new
pharmacokinetic data subsequently changed the maintenance therapy
administration to single-agent FAR 7.5 mg/kg once every three weeks.
Disease response and progression free survival was assessed utilizing
modiﬁed RECIST v1.0 based upon computed tomography (CT) scan or
magnetic resonance imaging (MRI) ﬁndings and by CA-125 levels
(i.e., CA-125 ≥ 2 × upper limit of normal documented on 2 occasions).
All patients were premedicated prior to FAR infusionwith acetamin-
ophen 650 mg by mouth and, optionally, diphenhydramine 25 mg to
50 mg IV or equivalent per clinic routine. In the event of a drug
hypersensitivity reaction believed to be associated with FAR, patients
were premedicated for subsequent infusions with antipyretic and
histamine receptor blockingmedications per clinic routine. Prophylactic
antiemetics were used for carboplatin and PLD according to usual
practice at each site.
All documents pertaining to study design, informed consent, and
patient information received Institutional Review Board approval in
accordance with the Declaration of Helsinki before the study began.
2.3. Safety and efﬁcacy evaluations
Safety assessments consisted of monitoring and recording all AEs
and serious AEs; performance of history and physical examinations;
regularmonitoring of hematology, blood chemistry, and urine laborato-
ry values (prior to treatment on Day 1,Week 1 of cycle 1); andmonitor-
ing with ECHO or MUGA at baseline and every third cycle during
combination therapy, then every fourth cycle during maintenance
therapy.
Efﬁcacy evaluations by modiﬁed RECIST v1.0 were performed at
screening, every second cycle during combination treatment, every
third cycle during maintenance, and at the study exit visit. Patients
who discontinued prior to disease progression for any other reason
(e.g., intolerable AE) were followed radiographically until documented
disease progression or initiation of a new anticancer treatment
occurred. As feasible, follow-up scans were obtained every 3 months;
CT or MRI scans were read locally.
2.4. Anti-drug antibodies
Patients weremonitored for the presence of ADA at screening, Day 1
of each combination treatment cycle, Day 1 of every third once-weekly
Fig. 1. Disposition of subjects across combination and maintenance treatment periods.
Table 1
Patient demographics and baseline disease characteristics.
All subjects
(N = 15)
Age, median (range), years 62.0 (47–82)
Age group, n (%)
18–b 65 years 10 (66.7)
≥65 years 5 (33.3)
Race white, n (%) 15 (100)
Ethnicity not Hispanic or Latino, n (%) 15 (100)
Karnofsky performance status, n (%)
100% 3 (20.0)
90% 12 (80.0)
Stage of disease, n (%)
IIC 3 (20.0)
IIIA 1 (6.7)
IIIC 8 (53.3)
IV 3 (20.0)
Histologic subtype, n (%)
Serous 10 (66.7)
Adenocarcinoma NOS 5 (33.3)
Primary site, n (%)
Fallopian tube 1 (6.7)
Ovary 14 (93.3)
Relapse, n (%)
First relapse 12 (80)
Second relapse 3 (20)
Length of ﬁrst remission, amean (SD), months 21.6 (13.47)
Length of ﬁrst remission, an (%), months
6 to b12 6 (40.0)
12 to b18 1 (6.7)
18 to 24 3 (20.0)
N24 5 (33.3)
a Length of ﬁrst remission is based on the platinum-based chemotherapy used prior to
study entry and is deﬁned as the period of time (in months) from the date of last dose of
platinum-based chemotherapy until date of ﬁrst relapse by RECIST or GCIG.
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dosing every 3 weeks), study exit visit, and 30 days post ﬁnal dose.
Associated FAR serum concentration and occurrence of a drug hyper-
sensitivity AE at the time of a positive ADA were identiﬁed. The
validated assay used for ADA analysis was estimated at 0.5 ng/mL
based on detection of a FAR-speciﬁc monoclonal IgG positive control
used as a surrogate ADA; the sensitivity was well below the FDA
minimum expected concentration of 250–500 ng/mL [13].
2.5. Statistical analysis
The target sample size for this studywas 15 patients. The sample size
for this study, 15 patients,was determined to be sufﬁcient to adequately
address the primary objective. No statistical comparisons were
performed that would require a minimum sample size for the study.
Safety analyses were performed on all patients who received at least
one dose of combination treatment. Safety datawere summarized using
descriptive statistics. For overall response and CA-125 response, the
number (percentage) of patients who responded was obtained and an
exact 2-sided 95% conﬁdence interval (CI) was constructed based on
Clopper-Pearson methodology [14]. For PFS, duration of response, and
time to response, the median was estimated using Kaplan-Meier
methodology [15]. The 2-sided 95% CI for the median was constructed
using the methodology of Brookmeyer and Crowley [16]. Two-sided
95% CIs for estimates of these endpoints at selected time points were
calculated using the log-log transformation [17].
3. Results
3.1. Patient disposition
This study was conducted at three centers in the United States be-
tween 18 May 2010 and 14 Aug. 2012. Fifteen patients were enrolled
and received at least one dose of FAR (Fig. 1). Carboplatin was dosed
at AUC5 in 8 patients and AUC6 in 7 patients. Patient demographics
and baseline characteristics are presented in Table 1. The median age
was 62.0 years (range 47–82). All patients were Caucasian. All but one
patient (with fallopian tube cancer) had a primary diagnosis of ovarian
cancer.
3.2. Safety
Fifteen patients received amedian of 12.0 cycles (range, 3–6) of FAR
as a component of combination therapy or as maintenance monothera-
py, 6 cycles (range, 3–9) during combination therapy and 6 cycles
(range, 3–26) during maintenance. The median length of exposure to
FAR was 45 weeks (range 9–95 weeks). Table 2 presents all related
AEs that occurred in more than one patient. During combination treat-
ment, the most common AEs were fatigue (73.3%), nausea (46.7%),
and neutropenia (40%). For single-agent maintenance (once weekly),
the most common AEs were peripheral edema (16.7%) and cough
(16.7%). During single-agent maintenance (once every three weeks),
the most common AE was urinary tract infection (25%). Ten patients
on combination treatment reported Grade 3 or higher AEs, the most
common being neutropenia (5 patients) and fatigue (2 patients). One
patient experienced Grade 3 palmar-plantar erythrodysesthesia (PPE).
Six patients (40%) experienced AEs that interrupted or delayed the
administration of chemotherapy. The most frequent AEs that delayed
or interrupted chemotherapy were neutropenia and PPE.
All 15 patients who received combination treatment reported
103 chemotherapy-related AEs. The most frequently reported
chemotherapy-related AEs were fatigue (66.7%), neutropenia
(40%), nausea (33.3%), PPE (33.3%), rash (33.3%), and alopecia
(26.7%). These percentages were comparable to those seen with
carboplatin/PLD only. Two patients (13.3%) experienced 2 drug
hypersensitivity AEs, hyperhidrosis and pruritus. Because of thedevelopment of ADAs, these were considered FAR related. Both
events occurred during combination treatment. Three of the 15
patients (20%) receiving FAR/carboplatin/PLD reported 11 AEs that
were considered (investigator judgment) related to FAR, the most
frequent being constipation and fatigue (2 patients each [13.3%]);
during maintenance, there were no AEs considered at least possibly
related to FAR.
Table 2
Treatment-related adverse events that occurred in more than one subject.
MedDRA system organ class/preferred
terma
FAR/carboplatin/PLD (N = 15)
FAR-related
n (%)b
Chemotherapy-related
n (%)b
Blood and lymphatic system disorders
Neutropenia 6 (40.0)
Anemia 2 (13.3)
Gastrointestinal disorders
Nausea 5 (33.3)
Diarrhea 3 (20.0)
Vomiting 3 (20.0)
Constipation 2 (13.3) 2 (13.3)
General disorders and administration site
conditions
Fatigue 2 (13.3) 10 (66.7)
Mucosal inﬂammation 3 (20.0)
Metabolism and nutrition disorders
Decreased appetite 3 (20.0)
Musculoskeletal and connective tissue
disorders
Pain in extremity 2 (13.3)
Nervous system disorders
Hypoesthesia 3 (20.0)
Dysgeusia 2 (13.3)
Neuropathy peripheral 2 (13.3)
Skin and subcutaneous tissue disorders
Palmar-plantar erythrodysesthesia
syndrome
5 (33.3)
Rash 5 (33.3)
Alopecia 4 (26.7)
FAR = farletuzumab, PLD = pegylated liposomal doxorubicin.
a Subjects may have more than one Preferred Termwithin a given System Organ Class.
b For each Preferred Term: n = number of subjects; % = percentages are based on the
number of subjects who received FAR/carboplatin/PLD.
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two with small bowel obstructions and one each with febrile neutrope-
nia and venous thrombosis. One patient experienced 3 serious AEs of
small bowel obstruction that were considered per investigator
judgment to be related to chemotherapy. None of the reported serious
events was related to FAR. Four of 15 patients (26.7%) tested positive
for ADA at least once while on study. Potential immunogenic reactions
to FAR occurred in two patients, one with grade 2 hyperdyrosis and
one with grade 1 pruritus. Seven patients (46.7%) experienced Grade 3
laboratory abnormalities while receiving FAR/carboplatin/PLD: 6 pa-
tients with decreased neutrophils, one with increased alanine amino-
transferase, and one with decreased white blood cell count. One
patient experienced a Grade 3 increase in glucose while receiving
maintenance treatment. No drug-induced liver events were identiﬁed.
No cardiac toxicity, deﬁned as a ≥ 15% decrease in LVEF from baseline
or ≥5% from institutional lower limit of normal, was observed during
chemotherapy or during FAR maintenance. All but 3 patients had the
same LVEF at last study assessment as they had at screening. Three
clinically not signiﬁcant decreases were noted (14%, 10%, 27%); overall,
the lowest value noted remained above the upper limit of normal for the
site.
No patient discontinued treatment during the study for any reason
other than disease progression, and no on-study deaths were reported.
3.3. Antitumor activity
Median radiologic PFS was 10.4 months (range 9.3–15.5); median
CA-125 PFS was 17.7 months (range 11.1–20.3). Best overall responses
by RECIST were a complete response for one patient, partial responses
for 10 patients, and stable disease for four patients. Median duration
of radiologic response was 8.4 months (range 6.9–13.6). Overall CA-
125 response occurred in 12 patients (80.0%) with 50% response, 8 pa-
tients (53.3%) with 75% response, and 10 patients (66.7%) withcomplete normalization of CA-125. and no patient had a study
remission length longer than the prior remission.
4. Discussion
While the standard treatment of platinum-sensitive EOC continues
to be debulking surgery followed by paclitaxel/carboplatin, adding a
third cytotoxic agent provided no improvement in either PFS or OS
when investigated in a Phase 3 study of 4312 women with advanced
stage EOC [18]. Recently, the combination of FAR plus carboplatin/
taxane (paclitaxel or docetaxel) was associated with high response
rates in patients with platinum-sensitive EOC at ﬁrst relapse, based on
results of a Phase 2 trial [7] and in a subset of patients in a subsequent
placebo-controlled Phase 3 trial [19]. The Phase 2 study of the efﬁcacy
of FAR plus carboplatin/taxane found normalization of CA-125 in
80.9% of patients, an objective response rate of 75%, as well as increased
duration of the progression-free interval (relative to the ﬁrst response
interval) in 21% of evaluable patients [7].
Though for many years carboplatin/paclitaxel has been regarded as
the treatment of choice at time of relapse for patients with platinum-
sensitive disease, recent clinical trial data have emerged to support
the use of carboplatin/gemcitabine or carboplatin/PLD as an alternative
to carboplatin/paclitaxel in this setting [9–11,20]. Carboplatin/PLD
appears to be better tolerated and includes the beneﬁt of a slight
improvement in PFS [9]. Additionally, there are some aspects of this
regimen that may be preferred by patients, including the lack of
propensity for alopecia and psychological implications of receiving a
new regimen (rather than retreatment with the original regimen,
which ultimately resulted in recurrence). The use of carboplatin/PLD
has increased since the aforementioned trials of FAR plus carboplatin/
paclitaxel. In Europe, as well as in major academic centers in the US, a
preference for carboplatin/PLD has evolved. However, in the US in
general, a preference for carboplatin/paclitaxel remains. Accordingly,
to assess the feasibility of adding FAR to the carboplatin/PLD combina-
tion, we undertook the Phase 1b safety study reported here in women
with platinum-sensitive EOC. In this study, FAR in combination with
carboplatin/PLD appeared to be generally well tolerated, with a safety
proﬁle consistent with that seen previously for FAR alone and in combi-
nation with the carboplatin/PLD regimen, where no additive toxicity
was found [7]. The majority of AEs were those expected with the
carboplatin/PLD combination chemotherapy backbone, including
neutropenia and PPE. Compared with 103 chemotherapy-related AEs,
there were 11 AEs that were considered by the investigators to be at
least possibly FAR-related, the most common being constipation and
fatigue at 2 reports each; however high-dose (10 mg/kg weekly)
single-agent FAR did not show similar effects [21]. Although
farletuzumab may be associated with fatigue, the incidence of fatigue
in this study was low compared with the ~40% reported in other
carboplatin/PLD studies [9,11]. No clinical safety concerns were noted
after the maintenance dose was modiﬁed, from FAR 2.5 mg/kg every
4 weeks to 7.5 mg/kg every 3 weeks, per the protocol amendment.
Although the efﬁcacy data reported here are preliminary, given that
this was a Phase 1b safety study, the CA-125 normalization rate of 67%
and objective response rate of 73% (11 of 15) are encouraging for this
study patient, which included patients in second as well as ﬁrst
platinum-sensitive relapse.
This Phase 1b study assessed the safety and tolerability of FAR plus
carboplatin/PLD as a ﬁrst step toward the pursuit of this triple-agent
regimen in future studies of EOC. Use of PLD as a replacement for
paclitaxel, speciﬁcally in the context of FAR, is also of interest, given
observations of immunosuppressive effects for paclitaxel in an ovarian
cell line (stemming from an observed interference with interleukin-2-
mediated immune system activation) [22], which could potentially
interfere with the immune-mediated mechanism of actions of FAR;
however, the clinical relevance of these preclinical ﬁndings is uncertain.
Nonetheless, in view of increased use of carboplatin/PLD in the
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combination plus a third agent appears warranted. Formal assessment
of efﬁcacy was not feasible given the study limitation of sample size in
this Phase 1 study. As supported by the favorable safety data described
here, a randomized, placebo-controlled Phase 2 study is planned
(MORAb-003-011 [NCT02289950]) to assess the efﬁcacy of FAR in
combination with carboplatin/PLD or carboplatin/paclitaxel (per
investigator choice) in patients with platinum-sensitive EOC (low CA-
125 at ≤3× upper limit of normal) at ﬁrst relapse, with PFS as the
primary endpoint.
In conclusion, we found that when FAR was combined with
carboplatin/PLD for the treatment of platinum-sensitive EOC, the safety
proﬁle was consistent with that of the doublet of carboplatin/PLD.
Further evaluation of FAR/carboplatin/PLD is underway.
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